Register Now
Why register?
Login
 The leading web portal for pharmacy resources, news, education and careers February 21, 2019
Pharmacy Choice - News - Pharmaceutical Industry Trends and Policy - February 21, 2019

Pharmacy News

 Pharmaceutical Industry Trends and Policy
Current Articles | 7 - 30 Days Old | 30 - 90 Days Old | Over 90 Days
Articles(s): 1 - 25 of 250     Next >>     Go To Page:

2/21/19 - 75 Biggest Movers From Yesterday
Gainers Kandi Technologies Group Inc shares gained 34.34 percent to close at $7.98 on Wednesday after the company reported NHTSA approval of 2 electric vehicle models. Arca Biopharma Inc shares surged 31.27 percent to close at $0.5080 on Wednesday after the company announced an agreement with the FDA for a single Phase 3 clinical trial to support a
2/21/19 - Smart drug shows promise for metastatic triple-negative breast cancer
A study has shown that a 'smart drug' that delivers a toxic payload directly to tumour cells could be a possible treatment for breast cancer... The post Smart drug shows promise for metastatic triple-negative breast cancer appeared first on European Pharmaceutical Review.
2/21/19 - AbbVie and Eisai Announce Fully Human Anti-TNF-alpha Monoclonal Antibody HUMIRA is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
With this approval, HUMIRA has become the first treatment indicated for HS in Japan, and is now approved for 11 indications in Japan. The approval of this additional indication is based on the data from a Japanese Phase III study and overseas clinical trials. In the clinical trial conducted in Japan, the percentage of patients who achieved the prim
2/21/19 - AbbVie reaches an agreement with the pan-Canadian Pharmaceutical Alliance (pCPA) for its hepatitis C treatment MAVIRET
-AbbVie, a global, research and development-based biopharmaceutical company, announced an agreement was reached with the pan- Canadian Pharmaceutical Alliance regarding MAVIRET?, a once-daily, ribavirin-free treatment for adults with chronic hepatitis C virus infection across all major genotypes 2. MAVIRET is the only 8- week, pan-genotypic treat
2/21/19 - Abeona Therapeutics Inc (NASDAQ:ABEO) had its Buy rating reiterated by HC Wainwright with a $30.00 price target
Analyst Ratings For Abeona Therapeutics Inc (NASDAQ:ABEO) Today, HC Wainwright reiterated its Buy rating on Abeona Therapeutics Inc (NASDAQ:ABEO) with a price target of $30.00. There are 8 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock. The current consensus rating on Abeona Therapeutics Inc (NASDAQ:ABEO) is Buy w
2/21/19 - ACADIA Pharmaceuticals to Present at the 8th Annual Leerink Partners Global Healthcare Conference on February 28, 2019
ACADIA Pharmaceuticals Inc., a biopharmaceutical company focused on the development and commercialization of innovative medicines that address unmet medical needs in central nervous system disorders, today announced that it will present at the 8 th Annual Leerink Partners Global Healthcare Conference on Thursday, February 28, 2019, at 9:30 a.m....
2/21/19 - Acasti Pharma Recognized in TSX Venture Exchange's 2019 Venture 50
Acasti Pharma Inc., a biopharmaceutical innovator focused on the research, development and commercialization of its prescription drug candidate CaPre for the treatment of severe hypertriglyceridemia, announces it has been recognized by the TSX Venture Exchange in its 2019 Venture 50, a ranking of the strongest companies on TSX Venture Ex
2/21/19 - Achaogen Announces Presentations at Two Upcoming Investor Healthcare Conferences [T-break Tech (Middle East)]
-Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the Company will be presenting at the following investor conferences:. 8th Annual Leerink Global Healthcare Conference on February 27th, 2019 at...
2/21/19 - Achaogen Announces Publication of Plazomicin Phase 3 CARE Study Results in the New England Journal of Medicine
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 CARE study of plazomicin in a Letter to the Editor. Achaogen's EPIC...
2/21/19 - Achaogen Announces ZEMDRI (plazomicin) Pivotal Phase 3 Study Results Published in the New England Journal of Medicine
Achaogen, Inc., a biopharmaceutical company discovering, developing and commercializing innovative antibacterial agents to address multi-drug resistant gram-negative infections, today announced that the New England Journal of Medicine has published the results from the Phase 3 EPIC study of ZEMDRI. Wagenlehner, M.D., Director, Clinic for Urology,
2/21/19 - Achieve Life Sciences Announces Completion of Enrollment in 254-Subject Phase 2b Trial of Cytisinicline for Smoking Cessation
SEATTLE- Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation, today announced the completion of full enrollment in the ORCA-1 trial of cytisinicline. ORCA-1 is the first in Achieve's ORCA Program, which aims to evaluate the effectivenes
2/21/19 - Achillion Pharmaceuticals Expands Operations and Clinical Development into Philadelphia Area Office Market
Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients and families affected by complement mediated diseases, today announced the expansion into a second office located at 1777 Sentry Parkway West in Blue Bell, Pa. The approximately 12,000 square-feet office space will serve as.
2/21/19 - Adamas to Present at Two Upcoming Investor Conferences [Egypt Independent]
-Adamas Pharmaceuticals, Inc., a fully-integrated pharmaceutical company pioneering time-dependent medicines for central nervous system disorders, today announced that Gregory T. Went, Ph.D., the Companys Founder, Chairman and Chief Executive, is scheduled to present at the following two investor conferences:. Leerink Partners Global Healthcare...
2/21/19 - Adamis Pharmaceuticals Publishes the Rationale for a Higher Dose Naloxone Product to Counter the Current Opioid Epidemic
SAN DIEGO- Adamis Pharmaceuticals Corporation announced today that the article entitled' Higher doses of naloxone are needed in the synthetic opioid era' has been published in the peer reviewed journal Substance Abuse Treatment, Prevention, and Policy. According to statistics published by the Centers for Disease Control and Prevention in 2017, drug
2/21/19 - Adial Pharmaceuticals Announces Partnership with Catalent to Package and Distribute Adial's AD04 for its Phase 3 Trial
This partnership brings together critical capabilities to allow the commencement of Adial's planned initial Phase 3 trial, with Catalent providing packaging and distribution. Catalent has a robust, global network, with the presence in Europe and the U.S. to provide flexible, integrated clinical supply services for investigational medicinal products
2/21/19 - Adial Pharmaceuticals Announces Pricing of $8.0 Million Underwritten Public Offering
Adial Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company focused on the development of medicines for addiction, today announced the pricing of an underwritten public offering of 2,475,000 shares of its common stock and warrants to purchase up to 1,856,250 shares of the Company's common stock. Maxim Group LLC is acting as the book-r
2/21/19 - Advanced Parenteral Drug Delivery Devices Market: Global Industry Analysis and Opportunity and Forecast 2019 To 2024
WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2024" reports to its database. WiseGuyReports.com adds "Advanced Parenteral Drug Delivery Devices Market 2019 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to
2/21/19 - ADVANZ PHARMA Corp. Announces Release Date for Fourth Quarter and 2018 Results
-ADVANZ PHARMA Corp., an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with continued access to high quality, niche established medicines, today announced it intends to release its fourth quarter and 2018 financial results before market open on Thursday, March 14, 2
2/21/19 - After accelerated approval, Merck`s Keytruda fails in liver cancer study [Sport360]
Merck& Co. disclosed Tuesday its cancer drug Keytruda failed a Phase 3 study in advanced liver cancer, less than four months after the immunotherapy gained an accelerated approval for a similar indication. In a statement, Merck Research Laboratories chief medical officer Roy Baynes called the efficacy results "generally consistent with findings fro
2/21/19 - Agfa Receives FDA 510(k) Clearance for DR 800 With Tomosynthesis
MORTSEL, Belgium, Feb. 21, 2019/ PRNewswire/. DR 800* offers one solution for radiography, fluoroscopy, tomography and advanced clinical applications. Tomosynthesis algorithms reconstruct images very quickly. MUSICA? Digital Tomosynthesis software processes the tomographic slices that are synthesized from a single tomographic sweep..
2/21/19 - Aimmune Therapeutics to Host Conference Call and Webcast to Discuss Fourth Quarter and Full-Year 2018 Financial Results and Recent Operational Highlights
Aimmune Therapeutics, Inc., a biopharmaceutical company developing treatments for life-threatening food allergies, today announced that it will host a conference call on Thursday, February 28, 2019, at 5:00 p.m. ET to discuss its financial results for the quarter and full-year ended December 31, 2018, and recent operational highlights.
2/21/19 - Alcoholics may benefit from multimillion-dollar grant for opioid-blocking implant, says Anaheim company [The Orange County Register]
BioCorRX, a small Anaheim company, believes it can help break this vicious cycle, and the National Institute on Drug Abuse is inclined to agree. The institute part of the National Institutes of Health has awarded BioCorRX a grant to help develop a naltrexone implant to treat what is officially called "opioid use disorder." BioCorRx in Anaheim,
2/21/19 - Alembic Pharmaceuticals announces USFDA Approval for Acetazolamide ExtendedRelease Capsules, 500 mg
Alembic Pharmaceuticals Limited today announced that it has received approval from the US Food& Drug Administration for its Abbreviated New Drug Application Acetazolamide Extended-Release Capsules, 500 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product Diamox Sequels, 500 mg, of Teva Branded Pharmaceutical...
2/21/19 - Amgen, Cytokinetics And Servier Announce Start Of METEORIC-HF, The Second Phase 3 Clinical Trial Of Omecamtiv Mecarbil In Patients With Heart Failure
THOUSAND OAKS, Calif., SOUTH SAN FRANCISCO, Calif., and SURESNES, France, Feb. 21, 2019/ PRNewswire/ Amgen, Cytokinetics, Incorporated and Servier today announced that METEORIC-HF, the second Phase 3 clinical trial of omecamtiv mecarbil, a novel cardiac myosin activator, is open to enrollment. Omecamtiv mecarbil is being developed for the potenti
2/21/19 - ARCA Biopharma Announces FDA Agreement for a Single Phase 3 Clinical Trial to Support Approval for the First Genetically-Targeted Cardiovascular Drug
WESTMINSTER- ARCA biopharma, Inc., a biopharmaceutical company applying a precision medicine approach to developing genetically-targeted therapies for cardiovascular diseases, today announced that it has reached agreement with the U.S. Food and Drug Administration regarding a Special Protocol Assessment on the design of a pivotal Phase 3 clinical..
Articles(s): 1 - 25 of 250     Next >>     Go To Page:


© 2019 Thomson Reuters. All rights reserved.

Pharmacy News Index
  Drug Delivery Systems
  Drugstores
  FDA Final Approvals
  Front Page Healthcare News
  Generic Drugs
  Hospital Industry
  Internet Pharmacy
  IT in Healthcare
  Medicare & Medicaid
  Over-the-Counter Drugs
  Pharm Industry Trends and Policy
  Pharmaceutical Development
  Pharmaceutical Industry

FEATURED CE LESSON

Legal & Practical Issues in Compounding Pharmacy
This lesson is supported by:
RxSchool
Men's Health in Older Adults: Benign Prostatic Hyperplasia and Erectile Dysfunction
This lesson is supported by:
RxSchool
Pharmacy Spanish
This lesson is supported by:
RxSchool

Special Announcement

Free Membership
Enjoy Drug Search, industry newsletters and more...


Websites » RxCareerCenter.comRxSchool.comClubStaffing.comNursingJobSource.comRN.com
Copyright © 2019 Pharmacy Choice - All rights reserved.
Terms and Conditions | Privacy Statement
888-682-4415